Navigation Links
Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
Date:4/20/2011

CARY, N.C., April 20, 2011 /PRNewswire/ -- Cetero Research, the leading early-phase contract research organization (CRO), will present a scientific seminar series for pharmaceutical and biotechnology researchers entitled "Practical Insights for Designing and Conducting an Accelerated Proof-of-Concept Program." The seminars, the continuation of a series that occurred in the fall of 2010, will share best practices on how to run successful studies by developing robust protocols, ensuring safety and recruiting effectively for innovative accelerated proof-of-concept study designs. The six-city tour will kick off on April 28 in Bridgewater, NJ.

"Pharmaceutical and biotechnology companies are very interested in the efficiencies that this approach can bring to their early-phase clinical studies. However, there are a number of complexities involved in developing these studies to successfully combine multiple protocols into a single study," said Troy W. McCall, Ph.D., Chief Executive Officer of Cetero Research. "Cetero leadership and independent industry experts will share case studies and best practices."

The scientific sessions will cover three aspects of Accelerated Proof-of-Concept (AcPOC) study design and conduct: protocol development, safety in first-in-human trials and patient recruitment strategies. The seminars will offer real-world advice on creating studies that strike a balance between the strict schedule to which accelerated studies must adhere and the built-in flexibility that these trials require for troubleshooting, efficiency and regulatory approval.

"With the accelerated approach, the protocol must be a living document that can be adjusted as you move through each component of the study. There needs to be flexibility in adapting to feedback from regulators and reactions from participants," sai
'/>"/>

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
2. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
3. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
4. Cetero Research Leads Industry in Human Allergy Models
5. Premier Research Re-brands its Medical Device Business Unit to D-TARGET
6. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
7. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
8. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
9. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
10. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
(Date:7/22/2014)... July 22, 2014 Getting breast implants is ... completely optional or due to medical necessity. Either way, women ... to prepare for it, says Robert Kraft, MD, Plastic Surgeon ... implant removal surgeries are performed each year in the United ... 70 percent of those procedures stem from three main problems: ...
(Date:7/22/2014)... Southlake, TX (PRWEB) July 22, 2014 ... proving to address skin laxity with results that are ... opposed to topically treating the skin with radio frequency, ... probes which are inserted under the skin to “inject” ... studies have shown that this single treatment solution for ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 PowerObjects, ... service, support, education, and add-ons for Microsoft Dynamics ... Inner Circle, an elite group of the most ... with sales achievements that rank them in the ... of partners. Members of the Microsoft Dynamics Inner ...
(Date:7/21/2014)... human nature to hate losing. , Unfortunately, it,s ... abandoning a solid strategy and thus increasing your chances ... conclusion of a Brigham Young University study published this ... finding is based on an analysis of two decades ... focused on whether coaches adjusted their personnel following games ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... HealthDay Reporter , TUESDAY, May 17 (HealthDay News) ... birth defects in women taking these drugs during the first ... the drugs are relatively new, further studies are needed to ... In a large study of children born in Denmark, ...
... City, the prevalence of asthma among children entering school ... children growing up within walking distance of each other ... asthma. In the first comprehensive effort to understand ... Mailman School of Public Health compared the household presence ...
... . , Pediatric and young adult leukemia and ... the Cole Foundation,s announcement that it would provide more than ... four McGill University young scientists. "The Cole Foundation is dedicated ... the age of 25, and the research projects we finance ...
... from Boston University School of Medicine (BUSM) have discovered ... syndromes. The team connected pharmacological properties of the Novartis ... for the first time after investigating adverse reactions suffered ... treatment of osteoporosis. These findings appear online in the ...
... -- A gene variation that causes faulty cholesterol regulation also ... may be a reason why some women can,t get pregnant, ... more than 200 infertile women who were undergoing in vitro ... the scavenger receptor class B type 1 (SCARB1) gene. ...
... the intermittent interruption of breathing that occurs in patients with ... cells and increased tumor growth in mice, according to researchers ... mouse models tended to contain more dead cells, indicating a ... the study will be presented at the ATS 2011 International ...
Cached Medicine News:Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 2Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 3Health News:Cockroach allergens in homes associated with prevalence of childhood asthma in some neighborhoods 2Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Obstructive sleep apnea linked to cancer growth in mice 2Health News:Obstructive sleep apnea linked to cancer growth in mice 3
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: